Mark Denison, MD

Edward Claiborne Stahlman Professor of Pediatrics
Department of Pediatrics, Vanderbilt University Medical Center and Vanderbilt University School of Medicine
Professor of Pathology, Microbiology & Immunology
Department Pathology, Microbiology and Immunology, Vanderbilt School of Medicine

Global Health Topic(s): Infectious Diseases, Pediatrics, Emerging Infections, Coronavirus Research

Country(ies): United States

Publications Link

 

Mark R. Denison, MD, is the Stahlman Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, and Director of the Division of Pediatric Infectious Diseases at Vanderbilt University Medical Center. The Denison Lab has been NIH funded for more than 30 years for investigation of the replication, pathogenesis, evolution, or coronaviruses, including SARS-CoV, MERS-CoV, and the current SARS-CoV-2 (COVID-19). Investigators in the Denison lab have identified multiple critical and unique viral enzymes as novel targets for antivirals and virus attenuation, including the proteases, RNA polymerase, and the novel CoV proofreading exonuclease. The Denison lab has focused on antiviral development since 2013 and directed preclinical testing for anti-CoV antivirals including Remdesivir and EIDD-2801 (Molupiravir).  Dr. Denison is a Fellow of AAAS, the American Academy of Microbiology, and the Association of American Physicians. 

Education

M.D., University of Kansas